Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases

Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases

Purpose: Finasteride and dutasteride are used to treat benign prostatic hyperplasia (BPH) and reduce the risk of developing prostate cancer. Finasteride blocks only the type 2 form of 5-alpha-reductase, whereas dutasteride blocks both type 1 and 2 forms of the enzyme. Previous studies suggest the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dae Yul Yang, Won-Woo Seo, Rae Woong Park, Sang Youl Rhee, Jae Myung Cha, Yoon Soo Hah, Chang Won Jeong, Kyung-Jin Kim, Hyeon-Jong Yang, Do Kyung Kim, Ji Yong Ha
Format:	Article
Language:	English
Published:	Korean Society for Sexual Medicine and Andrology 2025-01-01
Series:	The World Journal of Men's Health
Subjects:	dutasteride finasteride prostatic hyperplasia prostatic neoplasms
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

IMPROVING THE QUALITY OF PROSTATE TRANSURETHRAL RESECTION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA THROUGH INTRAOPERATIVE TRANSRECTAL ULTRASOUND MONITORING OF THE REMOVED TISSUE VOLUME
by: V. B. Filimonov, et al.
Published: (2019-06-01)

Potential clinical application of the cancer antigen CA‑62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate‑specific antigen
by: Zh. R. Cherkasova, et al.
Published: (2023-03-01)

The effect of systemic hypertension on prostatic arterial hemodynamics in dogs with benign prostate hyperplasia
by: Çağatay ESİN
Published: (2024-11-01)

Incidence of prostate adenocarcinoma in transurethral resection of the prostate patients
by: Yahia Ghazwani, et al.
Published: (2025-01-01)

Thulium laser enucleation of the prostate plus thulium fiber laser therapy for benign prostatic hyperplasia combined with bladder stones
by: Chen Wang, et al.
Published: (2024-08-01)

Rauwolfia vomitoria- a promising medical plant for benign prostatic hyperplasia management; yet with challenges
by: George Awuku Asare, et al.
Published: (2025-02-01)

Prostatic Artery Embolization: A Systematic Review Article
by: Pooja Atkuri, et al.
Published: (2025-01-01)

Influence of chronic ischemic disorders in the prostate on the development of benign prostatic hyperplasia
by: G. E. Roitberg, et al.
Published: (2020-06-01)

Comparison of Perioperative Outcomes of Holmium Laser Enucleation of the Prostate for Standard (≤149 ml) Versus Very Large (≥150 ml) Prostate Glands: Retrospective Analysis of a Propensity Score Matched Cohort of 326 Patients
by: Jacob Schmidt, et al.
Published: (2025-01-01)

Exploring the association between caffeine intake and benign prostatic hyperplasia: results from the NHANES 2005–2008
by: Fei Zhang, et al.
Published: (2025-01-01)

Alleviatory effect of isoquercetin on benign prostatic hyperplasia via IGF-1/PI3K/Akt/mTOR pathway
by: Young-Jin Choi, et al.
Published: (2024-05-01)

The Role of Immunohistochemistry for AMACR/p504s and p63 in Distinguishing Prostate Cancer from Benign Prostate Tissue Samples in Botswana
by: Ramatlho P, et al.
Published: (2025-01-01)

Magnitude and factors associated with benign prostatic hyperplasia among adult male patients visiting Wolaita Sodo University comprehensive specialized hospital southern Ethiopia
by: Tirufat Tiruneh, et al.
Published: (2024-12-01)

PHARMACOTHERAPY IN PATIENTS WITH ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA IN THE ABSENCE OF RISK OF DISEASE PROGRESSION
by: A. A. Kamalov, et al.
Published: (2018-03-01)

Burden of benign prostatic hyperplasia in the Middle East and North Africa Region, 1990–2021
by: Saeid Safiri, et al.
Published: (2025-02-01)

CHANGE IN TESTOSTERONE LEVELS IN ENDOSCOPIC OPERATIONS ON THE PROSTATE GLAND
by: E. A. Efremov, et al.
Published: (2018-06-01)

WATER versus WATER II 5‐year update: Comparing Aquablation therapy for benign prostatic hyperplasia in 30–80‐cm3 and 80–150‐cm3 prostates
by: Mohamad Baker Berjaoui, et al.
Published: (2024-11-01)

A Systematic Review of Medical Treatments for Benign Prostatic Hyperplasia in Dogs: Evaluating Strategies for Reproductive Function Preservation
by: Florin Petrișor Posastiuc, et al.
Published: (2025-01-01)

Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil
by: Juan Manuel Palacios, et al.
Published: (2025-01-01)

Application of mean maximum Young’s modulus value as a new parameter for differential diagnosis of prostate diseases
by: Nailei Huang, et al.
Published: (2025-01-01)

Quantitative estimation of drugs for erectile dysfunction and benign prostatic hyperplasia by high performance liquid chromatography: a review
by: Shalaka G. Gaonkar, et al.
Published: (2024-12-01)

Associations among immunophenotype, plasma metabolites, and benign prostatic hyperplasia: a mediation Mendelian randomization study
by: FAN Jiuming, et al.
Published: (2025-01-01)

The Novel Histological Prostatic Inflammation Score Helps Defining the Association Between Stromal and Glandular Inflammation with the Risk of Prostate Cancer at Prostate Biopsy
by: Ugo Giovanni Falagario, et al.
Published: (2025-01-01)

Association between prostate-specific antigen density and prostate cancer prediction among Nigerian men
by: Abudu EK, et al.
Published: (2025-01-01)

A comprehensive analysis of erectile dysfunction prevalence and the impact of prostate conditions on ED among US adults: evidence from NHANES 2001-2004
by: Yuhao Zhang, et al.
Published: (2025-01-01)

Purple corn extract improves benign prostatic hyperplasia by inhibiting 5 alpha-reductase type 2 and inflammation in testosterone propionate-induced rats
by: Sung-Ok Kim, et al.
Published: (2025-01-01)

Current biomarkers of prostate cancer
by: I. A. Aboian, et al.
Published: (2021-12-01)

Safety and feasibility of En‐bloc holmium laser enucleation for very large prostates (> 200 cc) with trainee involvement
by: Feres C. Maluf, et al.
Published: (2025-01-01)

A case of stromal sarcoma of the prostate with the incidental detection of prostate adenocarcinoma
by: Shang Xu, et al.
Published: (2025-03-01)

Oral Finasteride (5 mg and 2 mg) versus Topical Minoxidil 5% in Female Pattern Hair Loss
by: Eman Hamed El Morsy, et al.
Published: (2025-01-01)

The factors impacting on Gleason score upgrading in prostate cancer with initial low Gleason scores
by: Tzu-Heng Huang, et al.
Published: (2025-02-01)

Dutasteride nanoemulsion preparation to inhibit 5‐alpha‐hair follicle reductase enzymes in the hair follicle; an ex vivo study
by: Mehri Memar Bashi Aval, et al.
Published: (2023-02-01)

Features of conservative therapy of benign prostatic hyperplasia in patients with metabolic syndrome: " Treat to Target "
by: V. B. Filimonov, et al.
Published: (2020-12-01)

Analysis of the predictive value of the prostate-specific antigen-to-neutrophil ratio for the diagnosis of prostate cancer
by: Yuxuan Chen, et al.
Published: (2025-01-01)

A Rare Metastasis of Prostate Cancer
by: İlkin Hamid-Zada, et al.
Published: (2024-07-01)

Prostate Cancer Screening: Is it Recommended in 2024?
by: Dr. Ali Thwaini
Published: (2024-12-01)

The “prostate-pelvic syndrome” theory used in patients with type-III prostatitis and its correlation with prostate volume
by: Xiao-Ma Zhang, et al.
Published: (2025-01-01)

The boosting effect of minoxidil 0.1% when combined with dutasteride 0.01% and microneedling in the treatment of female pattern hair loss
by: Reham Essam, et al.
Published: (2024-01-01)

Malondialdehyde in benign prostate hypertrophy: a useful marker?
by: Rosaria Alba Merendino, et al.
Published: (2003-01-01)

Correlation of clinically significant prostate cancer sites across multiparametric MRI, prostate biopsy, and whole-mount pathology for optimal prostate biopsy strategy
by: Matteo Pacini, et al.
Published: (2025-02-01)